29 June 2022 | News
SCB-2019 (CpG 1018/Alum) as a third dose exhibited a 19-fold boost in neutralizing antibodies against Omicron BA.2 variant among baseline seronegative participants
Photo Credit: Freepik
China's Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced new positive clinical data in individuals vaccinated with a third dose of SCB-2019 (CpG 1018/Alum) as a homologous booster against the Omicron variant.
A homologous booster dose of SCB-2019 (CpG 1018/Alum) demonstrated a significant, 19-fold increase in neutralizing antibody levels against the Omicron BA.2 variant compared to pre-booster levels among baseline seronegative participants.
“This highly encouraging homologous booster data against Omicron represents a key milestone on Clover’s path to developing SCB-2019 for primary vaccination and as a universal COVID-19 booster vaccine to protect individuals in need, regardless of previous vaccination technology or infection history,” said Joshua Liang, Chief Executive Officer and Executive Director of Clover.
Dr. Nicholas Jackson, President of Global Research and Development of Clover said, “As part of our universal booster development for SCB-2019, we look forward to sharing additional clinical data, including top-line head-to-head data comparing SCB-2019 as a heterologous, 3rd booster dose against homologous 3rd booster doses of CoronaVac™ and Comirnaty® in Q3 2022.”
This double-blind, randomized, controlled study evaluated the immunogenicity and safety of SCB-2019 (CpG 1018/Alum) as a homologous booster dose administered approximately six months following a two-dose primary vaccination with SCB-2019 (CpG 1018/Alum).
In total, 3,755 participants were recruited in Brazil, the Philippines, and Columbia. Clover will further evaluate study participants for immunogenicity, durability, and safety, and intends to make data available in a manuscript for peer-review publication when available.